Rudi Scheerlinck is a certified GP (VUB; Brussels) with a Post-graduate in Pharmacology and Pharmaceutical Medicine (ULB; Brussels) and an executive MBA in International Management (SBS Swiss Business School, Zurich). He has a broad interest and experience in different fields within pharmacovigilance, including signal detection, medical analysis, management of safety issues, process improvement, and change management. He set up and led medical evaluation & risk management teams at UCB, GSK Biologicals, and Novartis Oncology, covering products in several therapeutic areas in pre- and post-marketing. Currently, he is Head Global Drug Safety at Basilea, a company active in the field of antibiotics, anti-fungals, and oncology.